Valeritas Holdings Inc

Valeritas — Investor Presentation (March 2018)

34 slides from Valeritas's investor presentation, Mar 12, 2018

  1. Slide 1: Valeritas Corporate Presentation March 2018

    Slide 1: Valeritas Corporate Presentation March 2018

    Valeritas Corporate Presentation NASDAQ: VLRX March 2018 ©2018 Valeritas, Inc.. Improving health and simplifying life for people with diabetes

  2. Slide 2: John Timberlake, CEO

    Slide 2: John Timberlake, CEO

    ©2018 Valeritas, Inc.. 2 NASDAQ: VLRX John Timberlake, CEO Improving health and simplifying life for people with diabetes

  3. Slide 3: Forward Looking Statements

    Slide 3: Forward Looking Statements

    Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicitation of an offer to purchase securities. Any sale by the company shall be made pursuant to a definitive purchase agreement. Unless otherwise stated in this presentation, references to “Valerita

  4. Slide 4: We know diabetes is a serious problem!

    Slide 4: We know diabetes is a serious problem!

    We know diabetes is a serious problem! ©2018 Valeritas, Inc.. 4 Insulin is the most potent glucose-lowering agent2 Do we really need another new insulin? 1. (1) American Diabetes Association Diabetes Fast Facts 2015. Available at https://www.professional.diabetes.org/content/fast-facts-data-and-stat

  5. Slide 5: Adherence to Multiple Daily Injections is Extremely Challenging

    Slide 5: Adherence to Multiple Daily Injections is Extremely Challenging

    ©2018 Valeritas, Inc.. 5 Adherence to Multiple Daily Injections is Extremely Challenging Especially Outside the Home Adherence Barriers2 • Impact to daily living • Embarrassment • Injection pain • Number of injections Forget to take injections3 53% Forget or don’t have their insulin supplies3 40% Sk

  6. Slide 6: Most Patients with Type 2 Diabetes on Insulin are NOT at Goal

    Slide 6: Most Patients with Type 2 Diabetes on Insulin are NOT at Goal

    ©2018 Valeritas, Inc.. 6 Most Patients with Type 2 Diabetes on Insulin are NOT at Goal1 6 20% AT A1c Goal 80% NOT AT A1c Goal Impact of Improving Glucose Control2 Deaths from Diabetes 21% Microvascular Complications 37% Heart Attacks 14% Peripheral Vascular Disease 43% 1. Grabner M, et al. Clinicoec

  7. Slide 7: Valeritas' Mission is for V-Go to be the Preferred Insulin Delivery Method

    Slide 7: Valeritas' Mission is for V-Go to be the Preferred Insulin Delivery Method

    ©2018 Valeritas, Inc.. Valeritas’ Mission is for V-Go® to be the Preferred Insulin Delivery Method for Patients with Type 2 Diabetes 7 Achieving this mission will ELIMINATE the need for Multiple Daily Injections of Insulin

  8. Slide 8: The V-Go Solution

    Slide 8: The V-Go Solution

    ©2018 Valeritas, Inc.. 8 The V-Go® Solution Breakfast Lunch Snack Dinner Bedtime Insulin delivery that is worn like a patch Only FDA & E.U. approved 24-hour, single-use, fully disposable insulin delivery device • that provides basal (background) and bolus (mealtime) insulin delivery • No batteries,

  9. Slide 9: Valeritas - Entering Growth Stage with Significant Market Opportunity

    Slide 9: Valeritas - Entering Growth Stage with Significant Market Opportunity

    Valeritas - Entering Growth Stage with Significant Market Opportunity ©2018 Valeritas, Inc.. 9 Entering Growth Stage • 3rd Consecutive quarter of growth • 40% of sales reps were hired in 2017 • Planned introduction of Bluetooth V-Go SIMTM Partnering • Executed distribution agreements in Italy & Puer

  10. Slide 10: Significant Market Opportunity for Valeritas in the U.S.

    Slide 10: Significant Market Opportunity for Valeritas in the U.S.

    ~ 4 .5 M N o t a t A 1c G o a l 5.6M Patients with Type 2 Diabetes On Insulin1 ©2018 Valeritas, Inc.. 10 Significant Market Opportunity for Valeritas in the U.S. U.S. Type 2 Diabetes 15% Initial V-Go® Target Market 2M Type 2 on Multiple Daily Shots Longer-Term V-Go Market (with V-Go pipeline product

  11. Slide 11: Sales & Marketing Model

    Slide 11: Sales & Marketing Model

    ©2018 Valeritas, Inc.. 11 Sales & Marketing Model PATIENT PHYSICIAN • Target high insulin volume prescribers • High frequency of office contact • High support & service for prescriber & patient • Activate patients to seek and ask for V-Go • Direct-to-Patient multi-channel marketing • Patient educati

  12. Slide 12: Evidence Strategy is Working Through Increasing Market Share

    Slide 12: Evidence Strategy is Working Through Increasing Market Share

    ©2018 Valeritas, Inc.. 12 Evidence Strategy is Working Through Increasing Market Share Q4 '16 Q1 '17 Q2 '17 Q3 '17 Q4 '17 3.3% 3.4% 3.5% 3.6% 3.7% 3.8% 3.9% 4.0% 4.1% 4.2% 4.3% V-Go® Share of Mealtime Insulin Prescriptions Average of All Valeritas Targeted Accounts

  13. Slide 13: Strong Prescription Growth from Targeted Accounts Driving Accelerating Revenue

    Slide 13: Strong Prescription Growth from Targeted Accounts Driving Accelerating Revenue

    ©2018 Valeritas, Inc.. 13 Targeted Accounts (Monthly TRx's) $2,000 $2,500 $3,000 $3,500 $4,000 $4,500 $5,000 $5,500 $6,000 $6,500 Q1'16 Q2'16 Q3'16 Q4'16 Q1'17 Q2'17 Q2'17 Q3'17 Q4'17 Quarterly Revenue (2015-2017) Strong Prescription Growth from Targeted Accounts Driving Accelerating Revenue Turning

  14. Slide 14: V-Go is Cost-effective for Both Payers & Patients

    Slide 14: V-Go is Cost-effective for Both Payers & Patients

    ©2018 Valeritas, Inc.. 14 V-Go® is Cost-effective for Both Payers & Patients Product is Primarily Fulfilled at Retail Pharmacy *What a Payor Pays (Net of Rebates & Co-pays when V-Go Contracted in Preferred Position) $17 / day calculated based on published Wholesale Acquisition Prices less estimated

  15. Slide 15: Strong Clinical Evidence

    Slide 15: Strong Clinical Evidence

    ©2018 Valeritas, Inc.. 15 Demonstrated Statistically Significant Improvements in A1C1-6 Improved Quality of Life1 Lowered Total Daily Dose of Insulin (Prescribed / Administered)1-6 11 48 Published Clinical Papers V-Go Patients Studied Presentations at National Conferences 1. Rosenfeld CR, et al. End

  16. Slide 16: Simple Titration Approach with V-Go Significantly Lowered A1C

    Slide 16: Simple Titration Approach with V-Go Significantly Lowered A1C

    ©2018 Valeritas, Inc.. 16 Use of a Simple Titration Approach with V-Go® Significantly Lowered A1C (glucose) Use of a weekly physician-driven mealtime dosing titration approach with patients with T2D uncontrolled on prior regimens 13% Before V-Go < 7% < 8% ≤ 9% On V-Go 47% 40% 87% 67% 100% A1C Goal A

  17. Slide 17: Patients Who Utilize V-Go Like How it Fits into Their Lifestyle

    Slide 17: Patients Who Utilize V-Go Like How it Fits into Their Lifestyle

    Patients Who Utilize V-Go® Like How it Fits into Their Lifestyle Extremely Satisfied = 39% Very Satisfied= 32% Satisfied= 16% Somewhat Satisfied= 7% Not Satisfied=6% >90% of Patients are satisfied with the ability of V-Go to fit with their Lifestyle N=720 patients prescribed V-Go dLife Survey 1Q 201

  18. Slide 18: Illustration of Life with Type 2 Diabetes

    Slide 18: Illustration of Life with Type 2 Diabetes

    ©2018 Valeritas, Inc.. 18 Illustration of Life with Type 2 Diabetes Thoughts from Actual V-Go® patients like Debbie and Jim • Living with type 2 diabetes was no longer manageable when my doctor asked me to take multiple daily shots of insulin. • Others would tell me it was my fault I had diabetes. •

  19. Slide 19: Valeritas Generated 45% Gross Margins at Significantly Lower Revenue

    Slide 19: Valeritas Generated 45% Gross Margins at Significantly Lower Revenue

    ©2018 Valeritas, Inc.. 19 Valeritas Generated 45% Gross Margins at Significantly Lower Revenue $5.8 $21.4 $27.0 $61.1 $- $10 $20 $30 $40 $50 $60 $70 Valeritas Q4'17 Dexcom Q2'11 Tandem Q3'17 Insulet Q3'13 Quarterly Revenue (1st Q Company reached 45% GM)* *Respective Company Public Filings. Gross Mar

  20. Slide 20: V-Go Line Extension Products Provide Path to the Broader Diabetes Market

    Slide 20: V-Go Line Extension Products Provide Path to the Broader Diabetes Market

    ©2018 Valeritas, Inc.. 20 V-Go® Line Extension Products Provide Path to the Broader Diabetes & Insulin Market V-Go® SIMTM (Simple Insulin Management)2 Expected to: • Provide connectivity to smart phones and data aggregation glucose meters and other devices • Permit tracking and reporting of basal ra

  21. Slide 21: V-Go with V-Go SIM Technology

    Slide 21: V-Go with V-Go SIM Technology

    ©2018 Valeritas, Inc.. 21 V-Go® with V-Go® SIMTM Technology (Simple Insulin Management)* The Future of Type 2 Diabetes Management PATIENT PHYSICIAN INDUSTRY PAYERS MANAGEMENT APPLICATIONS CLOUD HOSTING Partner * Product currently under development.

  22. Slide 22: Growth & Expansion Strategy

    Slide 22: Growth & Expansion Strategy

    ©2018 Valeritas, Inc.. Growth & Expansion Strategy 22 Increase market share within existing base of business (with current sales coverage) Grow share by expanding number of prescribers through increased sales coverage Maximize share and penetration with expanded R&D pipeline + High Touch / High Serv

  23. Slide 23: Financial Summary

    Slide 23: Financial Summary

    Financial Summary ($ in millions) 4th Quarter Summary 2H Summary 4Q17 4Q16 Change 2H-2017 2H-2016 Change Revenue $5.8 $4.8 +21% $10.8 $9.7 +12.3% Gross Profit $2.6 $1.8 +47% $4.6 $3.5 +32.0% Gross Margin 45.2% 37.1% +810 bp 42.7% 36.3% +640 bp Net Loss $15.5 $9.8 +57% $25.5 $19.0 +34.2% Cash Used in

  24. Slide 24: Investor Highlights

    Slide 24: Investor Highlights

    Investor Highlights Strong quarterly growth that will accelerate in 2018 and beyond Established reimbursement: Cost neutral / benefit to patients & payers V-Go® delivers clinically-relevant glucose lowering with less insulin 50% Gross Margin in Q4 2018 with ability to increase with additional sales

  25. Slide 25: Improving health and simplifying life for people with diabetes

    Slide 25: Improving health and simplifying life for people with diabetes

    ©2018 Valeritas, Inc.. 25 Improving health and simplifying life for people with diabetes NASDAQ: VLRX March 2018 ART-1236 Rev A 03/2018 Valeritas Corporate Presentation

  26. Slide 26: Appendix

    Slide 26: Appendix

    APPENDIX ©2018 Valeritas, Inc.. 26

  27. Slide 27: Significant Number of People with Diabetes Worldwide

    Slide 27: Significant Number of People with Diabetes Worldwide

    Significant Number of People with Diabetes Worldwide (2017 and 2045 est.) ©2018 Valeritas, Inc.. 27 IDF Diabetes Atlas, Eighth Edition, 2017

  28. Slide 28: Robust Clinical Data Validates the Ability of V-Go

    Slide 28: Robust Clinical Data Validates the Ability of V-Go

    Robust Clinical Data Validates the Ability of V-Go® to Deliver Clinically Relevant Reductions in A1C with Less Insulin 1. Abbott et al. Oral Presentation at the 77th Scientific Sessions of the ADA, June 2017. 2. Grunberger G, et al. Poster presented at AACE 23rd Annual Scientific Meeting, May 2014.

  29. Slide 29: Switching from Multiple Daily Injections to V-Go Results in Significant Reductions

    Slide 29: Switching from Multiple Daily Injections to V-Go Results in Significant Reductions

    Switching from Multiple Daily Injections to V-Go® Results in Significant Reductions in Total Insulin and A1C (glucose) ©2018 Valeritas, Inc.. 29 117 102 88 61* M e a n T o ta l Da il y D o s e o f In s ulin ( U /d a y ) Patient Reported Prescribed -1.2* C h a nge in A 1 C ( % ) n=86 *p<0.0001 compar

  30. Slide 30: Prospective Study Conducted by HealthCore, Inc.

    Slide 30: Prospective Study Conducted by HealthCore, Inc.

    ©2018 Valeritas, Inc.. 30 Prospective Study Conducted by HealthCore, Inc.1 Demonstrated V-Go® Improved A1C (lowered glucose) with Less Insulin -0.95* -0.46* Chan ge in A 1 C 1 HealthCore, Inc.., an outcomes research subsidiary of Anthem, Inc.. *Significant compared to baseline, Significant between

  31. Slide 31: V-Go with V-Go SIM Technology

    Slide 31: V-Go with V-Go SIM Technology

    V-Go® with V-Go SIMTM Technology (Simple Insulin Management)* The Future of Type 2 Diabetes Management PATIENT PHYSICIAN INDUSTRY PAYERS V-Go SIM sends data one-way to Smart Device. SIM app provides data on V-Go insulin dosages/timing. SIM app transfers data to Cloud. Cloud and other Apps can provid

  32. Slide 32: Scalable Business Model to Drive Shareholder Value

    Slide 32: Scalable Business Model to Drive Shareholder Value

    ©2018 Valeritas, Inc.. 32 V A L U E Scalable Business Model to Drive Shareholder Value CONTINUED GROTH IN U.S. WITH HIGH TOUCH / HIGH SERVICE MODEL SHORT-TERM 6 – 18 months MID-TERM 1. – 3 Years LONGER-TERM > 3 years Advance V-Go Next Gen / Line Extensions Expand Sales Force prudently in U.S. Begin

  33. Slide 33: Valeritas: Financial Summary – December 31, 2017

    Slide 33: Valeritas: Financial Summary – December 31, 2017

    Valeritas: Financial Summary – December 31, 2017 Financial Summary ($ in millions) Quarterly Summary Full Year Summary 4Q17 4Q16 Change 2017 2016 Change Revenue $5.8 $4.8 +21% $20.2 $19.6 +3.6% Gross Profit $2.6 $1.8 +47% $8.2 $6.9 +17.6% Gross Margin 45.2% 37.1% +810 bp 40.3% 35.5% +480 bp Cash Use

  34. Slide 34: V-Go Device Overview

    Slide 34: V-Go Device Overview

    • Simple filling does not require calculations, measuring or needles • Prevents accidental needle sticks Bolus Chamber Insulin Fluid Fluid Basal Chamber Piston Needle 24 hour Basal rate begins with the push of a button 4.6 mm, 30 gauge “Floating needle” On-demand bolus function is manually activated

Source: SEC EDGAR · 8-K filed Mar 12, 2018

More decks from Valeritas Holdings Inc